PhoenixBio Co., Ltd. (TYO:6190)
Japan · Delayed Price · Currency is JPY 497.00
+3.00 (0.61%)
Feb 17, 2026, 10:53 AM JST
PhoenixBio Revenue
PhoenixBio had revenue of 444.00M JPY in the quarter ending December 31, 2025, with 25.07% growth. This brings the company's revenue in the last twelve months to 1.60B, up 4.44% year-over-year. In the fiscal year ending March 31, 2025, PhoenixBio had annual revenue of 1.54B, down -10.15%.
Revenue (ttm)
1.60B
Revenue Growth
+4.44%
P/S Ratio
1.26
Revenue / Employee
23.16M
Employees
69
Market Cap
2.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.54B | -174.00M | -10.15% |
| Mar 31, 2024 | 1.72B | -409.00M | -19.26% |
| Mar 31, 2023 | 2.12B | 800.00M | 60.42% |
| Mar 31, 2022 | 1.32B | 311.00M | 30.70% |
| Mar 31, 2021 | 1.01B | -297.00M | -22.67% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.89B |
| Kohjin Bio | 5.07B |
| Soiken Holdings | 4.58B |
| Carna Biosciences | 579.06M |
| D. Western Therapeutics Institute | 387.00M |
| Kringle Pharma | 72.62M |
| Noile-Immune Biotech | 5.00M |
| FunPep Company | 3.00M |